Zobrazeno 1 - 10
of 43
pro vyhledávání: '"Daniel Wynn"'
Autor:
Enrique Alvarez, Lawrence Steinman, Edward J. Fox, Hans-Peter Hartung, Peiqing Qian, Sibyl Wray, Derrick Robertson, Krzysztof Selmaj, Daniel Wynn, Koby Mok, Yihuan Xu, Karthik Bodhinathan, Hari P. Miskin, Bruce A. C. Cree
Publikováno v:
Frontiers in Neurology, Vol 15 (2024)
BackgroundUblituximab is a novel anti-CD20 monoclonal antibody glycoengineered for enhanced antibody-dependent cellular cytotoxicity. The phase 3 ULTIMATE I and II studies showed significant improvements in annualized relapse rate, total number of ga
Externí odkaz:
https://doaj.org/article/130d74d067b24a7298186ec6d38aa0d2
Autor:
Mark S. Freedman, Patricia K. Coyle, Kerstin Hellwig, Barry Singer, Daniel Wynn, Bianca Weinstock-Guttman, Silva Markovic-Plese, Andrew Galazka, Fernando Dangond, Julie Korich, Anthony T. Reder
Publikováno v:
Neurology and Therapy, Vol 13, Iss 2, Pp 283-322 (2024)
Abstract Multiple sclerosis (MS) is a chronic, progressive, inflammatory disorder of the central nervous system. Relapsing–remitting MS (RRMS), the most common form of the disease, is characterized by transient neurological dysfunction with concurr
Externí odkaz:
https://doaj.org/article/8f4b63ea68774d85b40c2425f80dbef2
Autor:
Lawrence, Steinman, Edward, Fox, Hans-Peter, Hartung, Enrique, Alvarez, Peiqing, Qian, Sibyl, Wray, Derrick, Robertson, DeRen, Huang, Krzysztof, Selmaj, Daniel, Wynn, Gary, Cutter, Koby, Mok, Yanzhi, Hsu, Yihuan, Xu, Michael S, Weiss, Jenna A, Bosco, Sean A, Power, Lily, Lee, Hari P, Miskin, Bruce A C, Cree
Publikováno v:
New England Journal of Medicine. 387:704-714
The monoclonal antibody ublituximab enhances antibody-dependent cellular cytolysis and produces B-cell depletion. Ublituximab is being evaluated for the treatment of relapsing multiple sclerosis.In two identical, phase 3, double-blind, double-dummy t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cf08f64d37370fec503fd270f5149587
https://doi.org/10.1056/nejmoa2201904
https://doi.org/10.1056/nejmoa2201904
Autor:
Lawrence Steinman, Edward Fox, Hans-Peter Hartung, Enrique Alvarez, Peiqing Qian, Sibyl Wray, Derrick Robertson, Deren Huang, Krzysztof Selmaj, Daniel Wynn, Jenna Bosco, Koby Mok, Christopher A. Garner, Bruce Cree
Publikováno v:
Monday, April 24.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61bf79b3266c2f07ed0ed2cf9e7dd958
https://doi.org/10.1212/wnl.0000000000203095
https://doi.org/10.1212/wnl.0000000000203095
Autor:
Daniel, Wynn, Lawrence, Goldstick, William, Bauer, Enxu, Zhao, Eva, Tarau, Jeffrey A, Cohen, Derrick, Robertson, Aaron, Miller
Publikováno v:
CNS Neuroscience & Therapeutics. 28:364-371
About 20%-35% of multiple sclerosis (MS) patients fail to respond to high-dose corticosteroids during a relapse. Repository corticotropin injection (RCI, ActharThe study objective was to determine the efficacy and safety of RCI in patients with MS re
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edcbfa2df72a0723d8014db65c90a90a
https://doi.org/10.1111/cns.13789
https://doi.org/10.1111/cns.13789
Autor:
Regina, Berkovich, Donald, Negroski, Daniel, Wynn, Daniel, Sellers, Kristen G, Bzdek, Alex L, Lublin, Andreea M, Rawlings, Cuc, Quach, Danelle P, Wells, Melanie, Dumlao, Adriana, Bora, Anthony E, Ranno, Kevin Lin, Luo, Jeffrey, Chavin, Le H, Hua, Daniel, Becker
Publikováno v:
Multiple Sclerosis and Related Disorders. 70:104472
The prevalence of multiple sclerosis (MS) in older people is increasing due to population aging and availability of effective disease-modifying therapies (DMTs). Treating older people with MS is complicated by age-related and MS-related comorbidities
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::acf448432d8a889276fa152f57ecd218
https://doi.org/10.1016/j.msard.2022.104472
https://doi.org/10.1016/j.msard.2022.104472
Autor:
Daniel S Reich, Douglas L Arnold, Patrick Vermersch, Amit Bar-Or, Robert J Fox, Andre Matta, Timothy Turner, Erik Wallström, Xinyan Zhang, Miroslav Mareš, Farit A Khabirov, Anthony Traboulsee, Francois Grand'Maison, Francois Jacques, Michaela Tyblova, Eva Meluzinova, Radek Ampapa, Martin Valis, Pavel Hradilke, Pavel Stourac, Katrin Gross-Paju, David Laplaud, Guillaume Mathey, Bernard Uitdehaag, Evgeny Evdoshenkoo, Ekaterina Popova, Maria Zakharova, Natalia Totolyan, Igor Litvinenko, Farit Khabirov, Stella Sivertseva, Viera Hancinova, Ema Kantorova, Maria Luisa Martinez Gines, Xavier Montalban, Sara Eichau Maduano, Jose Meca-Lallana, Lluís Ramió-Torrentà, Tetyanna Nehrych, Valeriy Pashkovskyy, Sergii Moskovko, Oleksandr Kalbus, Marta Khavunka, Volodymyr Pryshchepa, Alla Goloborodko, Daniel Wynn, William Honeycutt, Sibyl Wray, Brian Steingo, Christopher LaGanke, Deren Huang, John Michael Hemphill, Lawrence Goldstick, Derrick Robertson
Publikováno v:
The Lancet. Neurology. 20(9)
Summary Background Tolebrutinib is an oral, CNS-penetrant, irreversible inhibitor of Bruton’s tyrosine kinase, an enzyme expressed in B lymphocytes and myeloid cells including microglia, which are major drivers of inflammation in multiple sclerosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b170032b6e1f2ca8a2cd0e24600173b7
https://pubmed.ncbi.nlm.nih.gov/34418385
https://pubmed.ncbi.nlm.nih.gov/34418385
Autor:
David J. Robbins, Joshua Jackson, Anmada Nayak, Ethan Lee, Ricardo A. Melendez, Daniel Wynn, Chen Shen, Yashi Ahmed
Publikováno v:
International Journal of Molecular Sciences, Vol 21, Iss 5940, p 5940 (2020)
International Journal of Molecular Sciences
International Journal of Molecular Sciences
Wnt signaling regulates numerous cellular processes during embryonic development and adult tissue homeostasis. Underscoring this physiological importance, deregulation of the Wnt signaling pathway is associated with many disease states, including can
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92431339b137946cbd0b2d4fb8dc3db8
https://www.mdpi.com/1422-0067/21/16/5940
https://www.mdpi.com/1422-0067/21/16/5940
Autor:
Fan Yang, Ethan Lee, Marta Garcia-Contreras, Maya Silver-Isenstadt, Huilan Wang, David J. Robbins, Sivanesan Dakshanamurthy, Daniel Wynn, Nagi G. Ayad, Yashi Ahmed, Bin Li, Anmada Nayak, Chen Shen, Leah M. Sawyer, Leif R. Neitzel, Hassina Benchabane, Charles H. Williams, Amber A Adams, Charles C. Hong, Nawat Bunnag, Anthony J. Capobianco
Publikováno v:
Nature Communications
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Nature Communications, Vol 12, Iss 1, Pp 1-10 (2021)
Immunomodulatory drugs (IMiDs) are important for the treatment of multiple myeloma and myelodysplastic syndrome. Binding of IMiDs to Cereblon (CRBN), the substrate receptor of the CRL4CRBN E3 ubiquitin ligase, induces cancer cell death by targeting k
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90740b3aea75f969e6949f527a6eebcc
https://pubmed.ncbi.nlm.nih.gov/34489457
https://pubmed.ncbi.nlm.nih.gov/34489457
Autor:
Daniel Wynn, David Margolin, Richard G Phelps, Glen S. Markowitz, Alasdair Coles, Mario Habek, Claudio E Rodriguez, Darren P Baker, Hans-Peter Hartung, Jonathan A. Winston, Eva Havrdova
Publikováno v:
Multiple Sclerosis (Houndmills, Basingstoke, England)
Phelps, R, Winston, J A, Wynn, D, Habek, M, Hartung, H-P, Havrdová, E K, Markowitz, G S, Margolin, D H, Rodriguez, C E, Baker, D P & Coles, A J 2019, ' Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis ', Multiple Sclerosis Journal, pp. 1352458519841829 . https://doi.org/10.1177/1352458519841829
Phelps, R, Winston, J A, Wynn, D, Habek, M, Hartung, H-P, Havrdová, E K, Markowitz, G S, Margolin, D H, Rodriguez, C E, Baker, D P & Coles, A J 2019, ' Incidence, management, and outcomes of autoimmune nephropathies following alemtuzumab treatment in patients with multiple sclerosis ', Multiple Sclerosis Journal, pp. 1352458519841829 . https://doi.org/10.1177/1352458519841829
Background: Autoimmune disorders including nephropathies have been reported more frequently in alemtuzumab-treated multiple sclerosis (MS) patients than in the general population. Objective: Describe instances of autoimmune nephropathy in alemtuzumab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28cbb60d65292860c592c902ee0dbb1c
https://pubmed.ncbi.nlm.nih.gov/31368417
https://pubmed.ncbi.nlm.nih.gov/31368417